Immune checkpoint blockade strategies are starting to be complemented by the addition of co-stimulatory molecule agonism with the goal of generating a more robust anti-tumor response. This approach warrants further investigation in order to find optimal combinations of targets and better inform future therapeutic options. Find the agonistic antibodies and small molecules you need below.
All of our agonistic (functional assay) antibodies are tested in-house in relevant bioassays and manufactured to ensure low endotoxin levels so you can be confident in their performance and trust the data you generate. Learn more about the R&D Systems approach to antibody quality. Click the boxes below to view our selection of agonistic antibodies for each co-stimulatory molecule listed.
|Human CD40/TNFRSF5 Antibody Stimulates Cell Proliferation in Human B Cells. Mouse Anti-Human CD40/TNFRSF5 Monoclonal Antibody (Catalog # MAB6321) stimulates human B cell proliferation in the presence of Recombinant Human IL 4 (Catalog # 204-IL) in a dose-dependent manner, as measured by Resazurin (Catalog # AR002). The ED50 for this effect is typically 0.035 0.175 μg/mL.|
TLR7 agonists promote the activation of dendritic cells and are being used to complement existing cancer immunotherapy strategies. Trust Tocris® small molecules for your research and enjoy unrivaled product quality, specialist technical support, and responsible and ethical practice. Click the box below to view our selection of TLR7 agonists.
Resiquimod is a TLR7 agonist that promotes the differentiation of MDSCs into macrophages and dendritic cells.
Download the brochure below and explore our interactive pathway for an informative graphical outline of T cell co-stimulatory and co-inhibitory molecules and to learn about our extensive offering of antibodies, proteins, and ELISAs for this area of research.